$3.42
2.84% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US51654W1018
Symbol
LTRN
Sector
Industry

Lantern Pharma Inc Stock price

$3.42
+0.31 9.97% 1M
-1.12 24.67% 6M
-0.86 20.09% YTD
-0.57 14.29% 1Y
-4.17 54.94% 3Y
-11.53 77.12% 5Y
-11.53 77.12% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.10 2.84%
ISIN
US51654W1018
Symbol
LTRN
Sector
Industry

Key metrics

Market capitalization $36.88m
Enterprise Value $9.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.39
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-21.20m
Free Cash Flow (TTM) Free Cash Flow $-17.24m
Cash position $28.05m
EPS (TTM) EPS $-1.77
P/E forward negative
Short interest 1.87%
Show more

Is Lantern Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Lantern Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Lantern Pharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Lantern Pharma Inc:

Buy
100%

Financial data from Lantern Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.18 0.18
6% 6%
-
-0.18 -0.18
6% 6%
-
- Selling and Administrative Expenses 5.40 5.40
9% 9%
-
- Research and Development Expense 15 15
46% 46%
-
-21 -21
26% 26%
-
- Depreciation and Amortization 0.18 0.18
6% 6%
-
EBIT (Operating Income) EBIT -21 -21
26% 26%
-
Net Profit -19 -19
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Lantern Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lantern Pharma Inc Stock News

Neutral
Business Wire
20 days ago
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progress...
Neutral
Business Wire
26 days ago
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer (TNBC). Th...
Neutral
Business Wire
about one month ago
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company transforming oncology drug development, and its wholly-owned subsidiary Starlight Therapeutics, focused exclusively on CNS and brain cancers, today announced the presentation of new preclinical data and Phase 1b trial design for LP-184 (to be developed as STAR-001 for CNS indications) in glioblastoma...
More Lantern Pharma Inc News

Company Profile

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on leveraging artificial intelligence (A.I.), machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, a non-hormone, non-chemotherapy, next generation alkylating agent with nanomolar potency that damages DNA in cancer cells that overexpress certain biomarkers indicated primarily in solid tumors, such as those in prostate and ovarian cancers. The company was incorporated in 2013 and is based in Dallas, Texas.

Head office United States
CEO Panna Sharma
Employees 21
Founded 2013
Website www.lanternpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today